Natera, Illumina Ink Deal To End Row Over DNA Testing IP

Law360 (May 13, 2020, 7:24 PM EDT) -- Illumina Inc. and Natera Inc. have agreed to drop dueling patent infringement claims over fetal DNA testing technology in California federal court and to firm up a licensing agreement, according to a newly submitted regulatory filing.

Natera said Tuesday in a filing with the U.S. Securities and Exchange Commission that the San Carlos, California, genetic testing company and its San Diego-based rival Illumina had come to an agreement to end the suit initially brought by Illumina as well as a countersuit.

"The settlement does not impact the ongoing inter partes review proceeding in the United States Patent and Trademark Office, or the pending patent opposition...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!